Navigation Links
Helix BioPharma reports Q2 2008 highlights, financial results
Date:3/10/2008

n the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. Reported financial information may not necessarily be indicative of future operating results or of future financial position, due to a number of risks and uncertainties, including those set forth below. This News Release contains certain forward-looking statements and information regarding the Company's activities and finances, which statements and information can be identified by the use of forward-looking terminology such as "future", "anticipation", "planned", "expects", "continue", "developing", or variations thereon, or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future and are inherently uncertain. Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation: uncertainty whether Topical Interferon Alpha-2b or L-DOS47 will be successfully developed and commercialized as a drug or at all; the need for additional clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; research and development risks, the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size a
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... DuPont Tate & Lyle Bio ... it has appointed Skidmore Sales & Distributing ... Essex Grain Products and Processor’s ... in the food and beverage markets. The ... mid-western states: Alabama, Arkansas, Connecticut, Delaware, Florida, ...
(Date:9/11/2014)... LONDON , Sept. 11, 2014 ... (CRT), the charity,s development and commercialisation arm, have reached ... biotechnology company in the emerging field of regenerative ... AST-VAC2 into clinical trials in subjects with non-small ... tenth treatment to enter Cancer Research UK,s Clinical ...
(Date:9/11/2014)... The Stem Cell Institute, located in ... umbilical cord stem cell therapy on Saturday, September 20, 2014 ... Resort from 1:00 pm to 4:00 pm. , Stem ... – “Umbilical Cord Stem Cell Clinical Trials for MS and ... founder of the Stem Cell Institute and Medistem Panama Inc. ...
(Date:9/10/2014)... Brunswick, New Jersey (PRWEB) September 11, 2014 ... will host its annual Innovations in Dermatological Sciences ... meeting will focus on how the university, industry ... dermatological research into clinical use. , This conference ... had experience with cross-sector collaboration, to share their ...
Breaking Biology Technology:DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 2DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 2Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 4Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 5Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 6Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 7Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 8Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 2Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 3Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 4Innovations in Dermatological Sciences 2014 2Innovations in Dermatological Sciences 2014 3
... Israel, June 17 BSP Ltd.,( http://www.bsp.co.il/pressall.asp ) ... non-invasive diagnosis and monitoring of Ischemic Heart,Disease, announced ... private,funding round, that included existing shareholders in the ... the HyperQ(TM), a cutting-edge technology that offers,highly reliable, ...
... a trend of unprecedented,growth in biotechnology innovation, targeted ... in the past year in,terms of development and ... at the 2008 BIO International Convention in San ... the need to measure,innovation in the market, in ...
... 17 /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ) ... in,a Phase 1 trial of PX-866 in patients ... compound designed to inhibit the activity of,phosphatidylinositol-3-kinase (PI-3K), ... a potent inhibitor of PI-3K, a component of ...
Cached Biology Technology:BSP Raises $2.6 Million Dollars From Private Investors 2In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study 2In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study 3In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study 4In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study 5Oncothyreon initiates Phase 1 trial of PX-866 cancer compound 2Oncothyreon initiates Phase 1 trial of PX-866 cancer compound 3Oncothyreon initiates Phase 1 trial of PX-866 cancer compound 4
(Date:9/12/2014)... happened on the way to dealing with climate ... dollars, worth of previously unreachable oil and natural ... and benefits from "fracking," which requires ... deep into underground rock formations, are the subject ... and government databases. The survey covers not only ...
(Date:9/11/2014)... autism often show a reduced frequency of social ... repetitive solitary behaviors. Autism has also been linked ... involved in processing emotions. Now Caltech researchers have ... that control whether the animal engages in social ... have implications for understanding neural circuit dysfunctions that ...
(Date:9/11/2014)... associate professor of mechanical engineering at Worcester ... the university,s Integrative Materials Design Center (iMdc), ... the National Science Foundation (NSF) to support ... manufacture metal-ceramic composites, which can be used ... efficient, while significantly increasing their performance. , ...
Breaking Biology News(10 mins):Stanford-led study assesses the environmental costs and benefits of fracking 2Stanford-led study assesses the environmental costs and benefits of fracking 3Stanford-led study assesses the environmental costs and benefits of fracking 4Tipping the balance of behavior 2Tipping the balance of behavior 3NSF funds new method for making materials that can make lighter, more efficient vehicles 2NSF funds new method for making materials that can make lighter, more efficient vehicles 3
... lab tests of "killer paper," a material intended for ... preserve foods by fighting the bacteria that cause spoilage. ... contains a coating of silver nanoparticles, which are powerful ... that silver already finds wide use as a bacteria ...
... contain atomic clues as to the habitats in which ... has important implications for predicting the effects of climate ... the animal kingdom. Applying a method previously only ... on plants, scientists from the University of Cambridge can ...
... MOUNTAIN VIEW, Calif., Jan. 10, 2011 Based ... monitoring market, Frost & Sullivan recognizes Cardiocom with ... for Enabling Technology. Cardiocom provides integrated clinical telehealth ... healthcare community. (Logo:   http://photos.prnewswire.com/prnh/20081117/FSLOGO ) ...
Cached Biology News:Insects hold atomic clues about the type of habitats in which they live 2Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 2Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 3Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 4
Fingerprinting II dimensioning techniques is an optional module that adds principal component analysis, multidimensional scaling, discriminant analysis and MANOVA, and self-organizing maps to the Fin...
Fingerprinting II Informatix optional matrix types module, is an optional module that adds external similarity and distance matrix functions to the Fingerprinting II Informatix software package....
... Dyad instrument is the most advanced thermal ... world-class thermal performance, the Dyad also boasts ... as point-and-click navigation via touch pad or ... easily and economically expanded to a four-bay ...
...
Biology Products: